560 KPL-716, anti-Oncostatin M receptor beta antibody, reduced pruritus in atopic dermatitis

KPL-716 is a fully-human monoclonal antibody against oncostatin M receptor beta (OSMR β), the shared receptor subunit for IL-31 and Oncostatin M (OSM) signaling. This First-In-Human, randomized, double-blind, placebo (PBO)-controlled phase 1b study assessed safety, tolerability, target engagement and Early Signal of Efficacy of single dose KPL-716 in adult subjects with moderate to severe atopic dermatitis (AD) experiencing pruritus (Worst Itch Numeric Rating Scale [WI-NRS] ≥7 at screening). The study consisted of 2 phases: KPL-716 monotherapy period (Day -7 to Day 28), when other AD medications were prohibited, and adjunctive therapy period (>Day 28), when subjects used topical corticosteroids as needed.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Interventional Studies, Clinical and Patient Outcomes Research Source Type: research